human small lung carcinoma a549  (ATCC)

Journal: bioRxiv

Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

doi: 10.64898/2026.02.17.706284

Figure Lengend Snippet: (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all NSCLC PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.

Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

Techniques: Viability Assay, Flow Cytometry, Clonogenic Assay, Control, Western Blot, Transfection, MANN-WHITNEY

Journal: bioRxiv

Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

doi: 10.64898/2026.02.17.706284

Figure Lengend Snippet:

Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

Techniques: Inhibition, Mutagenesis

Journal: bioRxiv

Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

doi: 10.64898/2026.02.17.706284

Figure Lengend Snippet: (a, b) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. (a) Left panels: representative immunoblots of the indicated proteins. GAPDH was used as a loading control. Right panels: densitometric quantification (fold change) of SF3B1, ATR or DNA-PKcs signal normalized to GAPDH signal. Mean ± SD. n=3. (b) RT-qPCR (fold change) of SF3B1 , ATR or PRKDC mRNA level. Mean ± SD. n = 3. (a, b) Mann-Whitney t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p<0.0001. (c) Correlation between SF3B1 and DNA-PKcs or ATR protein levels in a series of 77 NSCLC cell lines based on CCLE database. (d) Correlation between SF3B1 and PRKDC mRNA levels in lung adenocarcinoma patients retrieved from TCGA public database.

Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

Techniques: Transfection, Control, Western Blot, Quantitative RT-PCR, MANN-WHITNEY

Journal: bioRxiv

Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

doi: 10.64898/2026.02.17.706284

Figure Lengend Snippet: (a) Overall Rate Response (ORR) of all NSCLC PDXs (n = 25) treated with 4 mg/kg cisplatin, 5 mg/kg pladienolide B or a combination of both as compared to vehicle condition. Two-tails Mann-Whitney t test. ** p< 0.01, *** p< 0.001. (b) Probability of tumor progression (Relative Tumor Volume = 2) in control, pladienolide B-, cisplatin- or pladienolide B + cisplatin-treated PDXs. n = 7. Log-rank test. * p< 0.05, ** p < 0.01, *** p< 0.001. (c) LCF26 and ML1LC2 PDXs were treated with vehicle (ctrl), 4 mg/kg cisplatin, 5 mg/kg pladienolide B, or a combination of both. Left panels: immunoblots of DNA-PKCs and ATR. 3 PDXs/condition. GAPDH was used as a loading control. Right panels: normalized expression of DNA-PKcs or ATR according to GAPDH. Mann-Whitney t test. * p< 0.05, ** p< 0.01. (d) RT-PCR analysis of skipping of MLH3 -Ex8 in each PDX (3 distinct mice/PDX). Representative agarose gels of amplified products. Right numbers indicate amplicon size (in base pairs). Below numbers indicated the percentage of exon 8 exclusion. Mean ± SD.

Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

Techniques: MANN-WHITNEY, Control, Western Blot, Expressing, Reverse Transcription Polymerase Chain Reaction, Amplification

Journal: Molecules

Article Title: Synthesis and Biological Evaluation of β -Phenylalanine Derivatives Containing Sulphonamide and Azole Moieties as Antiproliferative Candidates in Lung Cancer Models

doi: 10.3390/molecules30153303

Figure Lengend Snippet: Non-proteogenic β -phenylalanine derivatives 2 – 14 demonstrated a structure-dependent antiproliferative activity in A549 cells. The cells were exposed to fixed 100 µM of compounds or doxorubicin (DOX), and cisplatin (CP) for 24 h, and the post-exposure viability was measured by MTT assay. The data is shown as mean ± SD of three experimental replicates.

Article Snippet: The A549 non-small cell human lung carcinoma cells (ATCC CCL-185), H69 (HTB-19), H69AR (CRL-11351), and HEK293 were obtained from the American Type Culture Collection (Rockville, MD, USA).

Techniques: Activity Assay, MTT Assay

Journal: Molecules

Article Title: Synthesis and Biological Evaluation of β -Phenylalanine Derivatives Containing Sulphonamide and Azole Moieties as Antiproliferative Candidates in Lung Cancer Models

doi: 10.3390/molecules30153303

Figure Lengend Snippet: Non-proteogenic β-phenylalanine derivatives 5 and 13b induce cell death in a 3D A549 spheroid model. ( A ) Representative images of AO/PI-stained A549 spheroids following 24 h treatment with test compounds, illustrating live (green) and dead (red) cells. ( B ) Quantification of compound-induced cytotoxicity measured by lactate dehydrogenase (LDH) release into the culture medium. Data are presented as mean ± standard deviation (SD) from three independent experiments. *** p < 0.002; **** p < 0.0001.

Article Snippet: The A549 non-small cell human lung carcinoma cells (ATCC CCL-185), H69 (HTB-19), H69AR (CRL-11351), and HEK293 were obtained from the American Type Culture Collection (Rockville, MD, USA).

Techniques: Staining, Standard Deviation

Journal: Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)

Article Title: Phytochemical Investigation and Cytotoxic Effect against A459 Cell Line via Iraqi Portulacaria afra (f. Protulacaea) Ethyl Acetate Whole Plant Extract

doi: 10.31351/vol34iss2pp144-154

Figure Lengend Snippet: Figure 4 . Dose-response curves of IC50 for assessment the effect of Portulacaria afra extract &Erlotinib against A549 cancer cells. Fig. A-C represents IC50 of positive control Erlotinib on A549 cell line. Fig. D-F represent IC50 of EAE of Portulacaia afra on A549 cell line after 24 hr., 48hr. ,and 72hr .

Article Snippet: Cell Culture The American Type Culture Collection ATCC (USA) provided the human lung non-small cell carcinoma cell line A549.

Techniques: Positive Control

Journal: Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)

Article Title: Phytochemical Investigation and Cytotoxic Effect against A459 Cell Line via Iraqi Portulacaria afra (f. Protulacaea) Ethyl Acetate Whole Plant Extract

doi: 10.31351/vol34iss2pp144-154

Figure Lengend Snippet: Figure 5. Cytotoxicity effects of the different concentration (250 mg/100ml, 500 mg/ml, 1000 mg/ml) of Extract of Portulacaria afra compared to Erlotinib against Human lung non-small carcinoma cell line A 549 after 24 hours (A), 48 hours (B) and 72 hours ( C). Morphological Comparison of lung cancer cells A549 upon exposure to Erlotinib and Portulacaria afra extract

Article Snippet: Cell Culture The American Type Culture Collection ATCC (USA) provided the human lung non-small cell carcinoma cell line A549.

Techniques: Concentration Assay, Comparison